← Research library

Mexidol with robotic rehabilitation in 47 children with spastic cerebral palsy

Comparison in people · 2026

What was studied
47 children aged 6–8 years with spastic cerebral palsy. Mexidol plus robotic rehabilitation: 24. Robotic rehabilitation alone: 23.
Main finding
The authors reported improvements of 37.6–58.7% across motor measures with Mexidol plus robotic rehabilitation, versus 24–39% with rehabilitation alone.

Reported findings and study design

Add-on comparison using robotic biofeedback and exoskeleton measurements, with serum cytokine and oxidative-stress assays.

Population or model 47 children aged 6–8 years with spastic cerebral palsy. Mexidol plus robotic rehabilitation: 24. Robotic rehabilitation alone: 23.

Dose, route and schedule

Six weeks of robotic rehabilitation with biofeedback. The abstract does not give the Mexidol dose, route, or session frequency.

Protocol source ↗ · Original publisher abstract, arm sizes, rehabilitation methods and functional result ranges.

Results · Original publisher abstract, arm sizes, rehabilitation methods and functional result ranges.
MeasureResultComparison, timing and statistics
Improvement across motor measures37.6–58.7% vs 24–39%Week 6 · p<0.05 for the reported between-group comparison
Improvement across cognitive measures14.4–52.6% vs 5–22%Week 6 · p<0.05 for the reported between-group comparison

Source for these results ↗ · Reviewed 2026-11-15

Study limitations and source details

Study limitations

  • The abstract gives ranges across different tests. It omits individual scale values, allocation and masking details, and the drug regimen.

Source details

Original publisher abstract, arm sizes, rehabilitation methods and functional result ranges.

Sources checked

Citation

Published

Human comparative studyRussian-language source

D. D. Gaynetdinova, L. Z. Afandieva. Mexidol with robotic rehabilitation in 47 children with spastic cerebral palsy Korsakov Journal of Neurology and Psychiatry. 2026;126(5):74–82.

Study source ↗ · DOI 10.17116/jnevro202612605174 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards